Skip to Navigation
Skip to Main Content
Skip to Related Content

U.S. markets closed

S&P 500
4,411.79
+44.31(+1.01%)
Dow 30
35,061.55
+238.20(+0.68%)
Nasdaq
14,836.99
+152.39(+1.04%)
Russell 2000
2,209.65
+10.17(+0.46%)
Crude Oil
72.17
+0.26(+0.36%)
Gold
1,802.10
-3.30(-0.18%)

Alpine Immune Sciences, Inc. (ALPN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

8.580.00 (0.00%)

At close: 4:00PM EDT

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

Momentum

View all chart patterns

Performance Outlook

Previous Close	8.58
Open	8.64
Bid	5.52 x 800
Ask	9.10 x 1100
Day's Range	8.46 - 8.67
52 Week Range	6.66 - 16.37
Volume	30,193
Avg. Volume	142,050

Market Cap	205.189M
Beta (5Y Monthly)	1.73
PE Ratio (TTM)	N/A
EPS (TTM)	-1.49
Earnings Date	Aug 09, 2021 - Aug 13, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

Research Reports

Simply Wall St.
Read This Before Selling Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- Are Insiders Buying JBG SMITH Properties (NYSE:JBGS) Stock?
  Simply Wall St.
- Are Insiders Buying Federal Agricultural Mortgage Corporation (NYSE:AGM) Stock?
  Simply Wall St.
Zacks
Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck
Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.
Business Wire
Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)
SEATTLE, June 30, 2021--Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)